The pharmaco-epidemiological study about serious and opportunistic infections under treatment of the biologics and the molecular target medicine.

生物制剂和分子靶向药物治疗下严重和机会性感染的药物流行病学研究。

• 批准号: 23590171
• 负责人: TANAKA Michi
• 金额: $ 3.33万
• 依托单位: Tokyo Medical and Dental University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23590171/
• 关键词: リウマチ性疾患; 関節リウマチ; 免疫抑制療法; 生物学的製剤; 肺感染症; 日和見感染症; 膠原病; 分子標的薬; 重篤肺感染症; 日和見肺感染症; 薬剤疫学研究

Prospective cohort study to identify risk factors for development of pulmonary infection in patients receiving immunosuppressive treatment for rheumatic diseases.: 766 patients with rheumatic disease enrolled. Older age, higher Brinkman index, higher serum Cr level, and disturbed performance status were significantly associated with development of pulmonary infection.Pneumocystis jirovecii pneumonia (PCP) in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.: Data from 17 RA patients who were diagnosed with PCP and from 89 RA patients who did not develop PCP during adalimumab treatment were collected. The patients with PCP were significantly older and had more structural changes than the patients without PCP.

前瞻性队列研究，以确定风湿性疾病患者接受免疫抑制治疗后发生肺部感染的风险因素。766例风湿性疾病患者入组。年龄较大、Brinkman指数较高、血清Cr水平较高和体力状态紊乱与肺部感染的发生显著相关。接受阿达木单抗治疗的类风湿性关节炎患者的耶氏肺孢子虫肺炎（PCP）：17例患者的回顾性回顾和病例对照研究。收集了阿达木单抗治疗期间17例诊断为PCP的RA患者和89例未发生PCP的RA患者的数据。PCP患者的年龄明显大于非PCP患者，且结构改变更多。

项目成果

CLINICAL CHARACTERISTICS OF AND RISK FACTORS FOR Pneumocystis jirovecii PNEUMONIA IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TNF ANTAGONISTS.

接受 TNF 拮抗剂的类风湿性关节炎患者的耶氏肺孢子虫肺炎的临床特征和危险因素。

• 发表时间: 2011
• 作者: Tsutomu Sakuma;Satomi Ikematsu;Yuka Kurimoto;Yuki Kawasaki;Nobuo Nemoto;M. Harigai.
• 通讯作者: M. Harigai.

How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report From a Large-Scale Prospective Cohort Study

如何评估接受风湿病免疫抑制治疗的患者肺部感染的风险？

• 发表时间: 2012
• 作者: Tajima H;Kitagawa H;Tsukada T;Okamoto K;Nakanuma S;Sakai S;Makino I;Furukawa H;Hayashi H;Oyama K;Inokuchi M;Nakagawara H;Miyashita T;Itoh H;Fujita H;Takamura H;Ninomiya I;Fushida S;Fujimura T;Ohta T;Koda W;Minami T;Ryu Y;Sanada J;G;Hayato Yamazaki et al.
• 通讯作者: Hayato Yamazaki et al.

TNF阻害薬使用関節リウマチ患者におけるニューモシスチス肺炎

使用 TNF 抑制剂治疗类风湿性关节炎患者的肺孢子虫肺炎

• 发表时间: 2012
• 作者: 佐久間勉;河崎優希;古野幸美;後藤雄真;茂木優治;根本信雄;櫻井宏明;渡部香織
• 通讯作者: 渡部香織

アダリムマブ使用関節リウマチ患者におけるニューモシスチス肺炎

使用阿达木单抗治疗类风湿性关节炎患者的肺孢子菌肺炎

• 发表时间: 2011
• 作者: 伊藤祐介;深見達基;中島美紀;横井毅;渡部香織
• 通讯作者: 渡部香織

膠原病における免疫抑制療法下の肺感染症に関する前向き研究

胶原病免疫抑制治疗下肺部感染的前瞻性研究

• 发表时间: 2013
• 作者: Chatuphonprasert W.;Nemoto N.;Sakuma T.;and Jarukamjorn K.;山崎隼人
• 通讯作者: 山崎隼人